Skip to search formSkip to main contentSkip to account menu

MGCD516

Known as: Multitargeted Kinase Inhibitor MGCD516 
An orally bioavailable, receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic activity. Upon administration, multitargeted kinase… 
National Institutes of Health

Related topics

Related topics

3 relations
NCIt Antineoplastic Agent TerminologyReceptor Tyrosine Kinase Inhibition

Broader (1)

sitravatinib

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
The Efficacy of Lenvatinib Plus Everolimus in Patients with Metastatic Renal Cell Carcinoma Exhibiting Primary Resistance to Front-Line Targeted Therapy or Immunotherapy.
2020
2020
Sitravatinib, a Tyrosine Kinase Inhibitor, Inhibits the Transport Function of ABCG2 and Restores Sensitivity to Chemotherapy-Resistant Cancer Cells in vitro
Sitravatinib, also called MGCD516 or MG-516, is a broad-spectrum tyrosine kinase inhibitor (TKI) under phase III clinical… 
2017
2017
Multitargeted Imidazoles: Potential Therapeutic Leads for Alzheimer’s and Other Neurodegenerative Diseases
Alzheimer’s disease (AD) is a complex, multifactorial disease in which different neuropathological mechanisms are likely involved… 
2016
2016
Design, synthesis and biological evaluation of 6-substituted pyrrolo[2,3-d]pyrimidines as dual inhibitors of TS and AICARFTase and as potential antitumor agents.
Highly Cited
2015
Highly Cited
2015
Significant blockade of multiple receptor tyrosine kinases by MGCD516 (Sitravatinib), a novel small molecule inhibitor, shows potent anti-tumor activity in preclinical models of sarcoma
Sarcomas are rare but highly aggressive mesenchymal tumors with a median survival of 10–18 months for metastatic disease… 
2015
2015
A first in human phase I study of receptor tyrosine kinase (RTK) inhibitor MGCD516 in patients with advanced solid tumors.
2575Background: MGCD516 is an oral, potent small molecule inhibitor of a closely related spectrum of RTKs including RET, TRK… 
Review
2014
Review
2014
Intersection of Cardiology and Oncology Clinical Practices
Globally, cancer is diagnosed in approximately 13 million people each year. Approximately 1.6 million cancer patients are seen by… 
2013
2013
Synergistic anti-cancer effects of resveratrol and chemotherapeutic agent clofarabine against human malignant mesothelioma MSTO-211H cells.
2012
2012
Multitargeted Tyrosine Kinase Inhibition Produces Discordant Changes Between 99mTc-MDP Bone Scans and Other Disease Biomarkers: Analysis of a Phase II Study of Sunitinib for Metastatic Castration…
One of the central unanswered questions in prostate cancer research is the significance of tyrosine kinase inhibitor (TKI… 
Review
2007
Review
2007
Role of tyrosine kinase inhibitors in the treatment of advanced colorectal cancer.
Colorectal cancer (CRC) is a common health problem in Western countries. In advanced disease, either FOLFOX (oxaliplatin/5… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)